Heart failure patients with few options find future in mechanical devices
The Joint Commission has approved UC San Diego Health System’s Disease-Specific Care Certification for Ventricular Assist Device (VAD). Hospitals performing VAD as a “destination therapy” (for permanent use) receive a certification of distinction and receive reimbursement from Centers for Medicare and Medicaid Services… Read the full story from the UCSD Newsroom
UCSD Medical Center investigators are enrolling patients in a Phase 2 clinical trial of MYDICAR®, a new gene therapy for advanced heart failure.
The drug is designed to boost the efficiency of the heart by restoring a crucial heart enzyme.
UCSD cardiologist Dr. Barry H. Greenberg is principal investigator of the UCSD portion of the study, which is known as the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial.